STOCK TITAN
  1. Home
  2. News
  3. CDTX

Cidara Therapeutics, Inc. - CDTX STOCK NEWS

Welcome to our dedicated page for Cidara Therapeutics news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics stock.

Cidara Therapeutics, Inc. (CDTX), headquartered in San Diego, California, is a pioneering biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company's mission is to address diseases inadequately treated by current standard of care therapies. Utilizing its proprietary Cloudbreak® platform, Cidara develops drug-Fc conjugates (DFCs) aimed at saving lives and improving patient outcomes for serious diseases such as cancer, viral infections, and autoimmune diseases.

The company's core portfolio includes:

  • Rezafungin (REZZAYO™): An FDA and EC-approved treatment for invasive candidiasis, licensed to multiple partners for commercialization in the U.S. and internationally.
  • CD101 IV: A potential once-weekly intravenous therapy for systemic fungal infections.
  • CD101 Topical: The first topical application of the echinocandin class of anti-fungals for vulvovaginal candidiasis (VVC).
  • CD388: A long-acting antiviral investigational drug for the prevention of all strains of influenza A and B, currently in Phase 2b development.

Recent achievements include significant data presentations at prestigious conferences and strategic realignments to focus on the most promising components of their pipeline. Cidara’s financial stability is reinforced by a $240 million private placement led by RA Capital Management, with participation from top-tier investors like Bain Capital Life Sciences and Biotech Value Fund (BVF).

Noteworthy partnerships include collaborations with Johnson & Johnson for CD388 and Mundipharma for the divestiture of rezafungin, which has led to substantial cost savings and allows Cidara to focus on its Cloudbreak platform. The company is also preparing for a Phase 2b clinical trial of CD388, aiming to deliver universal, season-long protection against influenza.
For more information, visit www.cidara.com.

News

Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023

Rhea-AI Summary
Cidara Therapeutics to host virtual R&D Day, providing updates on Phase 2a data for JNJ-0953 drug candidate for universal prevention of seasonal influenza and insights into oncology DFCs targeting solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News

Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference

Rhea-AI Summary
Cidara Therapeutics to present at H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
-
News

Cidara Therapeutics Announces Janssen’s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza

Rhea-AI Summary
Janssen Pharmaceuticals has elected to proceed with CD388, an influenza prevention drug being developed by Cidara Therapeutics. Cidara will receive a $7 million milestone payment and could potentially earn $685 million in milestones and royalties. CD388 has shown promising interim efficacy and safety data in Phase 1 and 2a trials, with a single dose decreasing viral replication and lowering influenza incidence rate compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.1%
Tags
none
News

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Rhea-AI Summary
Cidara Therapeutics appoints Dr. Nicole Davarpanah as Senior VP of Translational Research & Development. She will lead the company's oncology efforts and focus on the strategy for developing drug candidates. Dr. Davarpanah brings expertise in immuno-oncology drug development and corporate development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
management
-
News

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Cidara Therapeutics, Inc. (Nasdaq: CDTX) reported financial results for Q2 2023, with a focus on the progress of its Cloudbreak platform, including Fast Track designation for CD388 in collaboration with Janssen Pharmaceuticals, and ongoing preclinical studies for CD421. Recent corporate highlights include REZZAYO™ commercialization by Melinta, update on the CD388 influenza program, and FDA granting Fast Track designation to CD388. Cidara also joined the Russell Microcap® Index and presented at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit. Financially, revenue increased to $7.6 million for Q2 2023, with cash and cash equivalents totaling $50.4 million. Research and development expenses were $17.1 million, and general and administrative expenses were $3.3 million. Net loss for Q2 2023 was $12.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
earnings
-
News

Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)

Rhea-AI Summary
Cidara Therapeutics announces the commercial launch of REZZAYO™ (rezafungin for injection) by its U.S. partner, Melinta Therapeutics. The European Medicines Agency (EMA) is currently reviewing the marketing authorization application (MAA) for rezafungin, with a decision expected by year-end 2023. The total potential transaction value of the Melinta License Agreement is $460.0 million, including upfront and milestone payments. Cidara retains the rights to rezafungin in Japan and is evaluating potential commercial partnerships in the country.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
News

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
none
-
News

Cidara Therapeutics Added to Russell Microcap® Index

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
-
News

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
clinical trial
News

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
conferences

FAQ

What is the current stock price of Cidara Therapeutics (CDTX)?

The current stock price of Cidara Therapeutics (CDTX) is $23.22 as of December 20, 2024.

What is the market cap of Cidara Therapeutics (CDTX)?

The market cap of Cidara Therapeutics (CDTX) is approximately 252.1M.

What is Cidara Therapeutics' primary focus?

Cidara Therapeutics focuses on discovering, developing, and commercializing novel anti-infectives and immunotherapies for diseases inadequately treated by current therapies.

What is the Cloudbreak® platform?

The Cloudbreak® platform is Cidara's proprietary technology used to develop drug-Fc conjugates (DFCs) that target serious diseases by combining small molecules and peptides with human antibody fragments.

What are some of Cidara's key products?

Key products include REZZAYO™ (rezafungin) for invasive candidiasis, CD101 IV for systemic fungal infections, CD101 Topical for vulvovaginal candidiasis, and CD388 for the prevention of influenza A and B.

Has Cidara received any approvals for its products?

Yes, Cidara has received FDA and EC approval for REZZAYO™ (rezafungin) for the treatment of invasive candidiasis.

What recent strategic decisions has Cidara made?

Cidara recently divested rezafungin to Mundipharma, resulting in significant cost savings, and reacquired the global rights to CD388 from Johnson & Johnson to focus on their Cloudbreak platform.

How is Cidara funded?

Cidara is funded through investments, including a $240 million private placement led by RA Capital Management, and milestone payments from collaborations with partners like Mundipharma and Johnson & Johnson.

What upcoming clinical trials does Cidara have?

Cidara is planning to initiate a Phase 2b clinical trial to evaluate the efficacy and safety of CD388 as a universal preventative for influenza.

Where is Cidara Therapeutics headquartered?

Cidara Therapeutics is headquartered in San Diego, California.

Who are Cidara's major partners?

Major partners include Johnson & Johnson for CD388 and Mundipharma for rezafungin.

How can I get more information about Cidara?

For more information, you can visit Cidara's official website at www.cidara.com.

Stock CDTX logo
Cidara Therapeutics, Inc.

Nasdaq:CDTX

CDTX Rankings

#3665 Ranked by Market Cap
N/A Ranked by Dividends

CDTX Stock Data

252.14M
10.85M
4.73%
51.86%
0.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO